Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing.

Antimicrobial Agents and Chemotherapy
Elizabeth M StreicherRob M Warren

Abstract

The global emergence of multidrug-resistant tuberculosis has highlighted the need for the development of rapid tests to identify resistance to second-line antituberculosis drugs. Resistance to fluoroquinolones and aminoglycosides develops through nonsynonymous single nucleotide polymorphisms in the gyrA and gyrB genes and the rrs gene, respectively. Using DNA sequencing as the gold standard for the detection of mutations conferring resistance, in conjunction with spoligotyping, we demonstrated heteroresistance in 25% and 16.3% of Mycobacterium tuberculosis isolates resistant to ofloxacin and amikacin, respectively. Characterization of follow-up isolates from the same patients showed that the population structure of clones may change during treatment, suggesting different phases in the emergence of resistance. The presence of underlying mutant clones was identified in isolates which failed to show a correlation between phenotypic resistance and mutation in the gyrA or rrs gene. These clones harbored previously described mutations in either the gyrA or rrs gene, suggesting that rare mutations conferring resistance to ofloxacin or amikacin may not be as important as was previously thought. We concluded that the absence of a correl...Continue Reading

References

Oct 1, 1995·Clinical Microbiology Reviews·J M Musser
Jul 13, 2000·Lancet·A Van RieP D Van Helden
Jan 5, 2002·Journal of Medical Microbiology·H Rinder
Nov 26, 2003·Infection and Immunity·Gilla KaplanLinda-Gail Bekker
Jan 1, 2004·American Journal of Respiratory and Critical Care Medicine·Robin M WarrenPaul D van Helden
Feb 26, 2004·American Journal of Respiratory and Critical Care Medicine·Marcel A Behr
Dec 8, 2004·Journal of Clinical Microbiology·Isdore Chola ShamputaFrançoise Portaels
Jun 11, 2005·American Journal of Respiratory and Critical Care Medicine·Annelies van RieRobin M Warren
Oct 27, 2006·Journal of Clinical Microbiology·E M StreicherR M Warren
Nov 1, 2006·Emerging Infectious Diseases·Vladyslav NikolayevskyyFrancis Drobniewski
Apr 21, 2007·Tropical Medicine & International Health : TM & IH·Mukund Uplekar, Knut Lönnroth
Nov 9, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Manormoney Pillay, A Willem Sturm
Jan 19, 2008·American Journal of Respiratory and Critical Care Medicine·Marinus BarnardMarlein E Bosman
Jun 24, 2008·Travel Medicine and Infectious Disease·Lindsay MartinezMario Raviglione
Nov 29, 2008·The New England Journal of Medicine·Helen S CoxStefan Niemann
Feb 13, 2009·PLoS Medicine·Andreas SandgrenMegan B Murray
May 28, 2010·Journal of Clinical Microbiology·Robert BlakemoreDavid Alland
Aug 3, 2010·Infectious Disease Clinics of North America·Keertan DhedaMartin P Grobusch
Sep 10, 2010·The New England Journal of Medicine·Catharina C BoehmeMark D Perkins
Apr 16, 2011·American Journal of Respiratory and Critical Care Medicine·Grant TheronKeertan Dheda

❮ Previous
Next ❯

Citations

Oct 23, 2012·American Journal of Respiratory and Critical Care Medicine·Marinus BarnardRichard O'Brien
Feb 1, 2014·Evolution, Medicine, and Public Health·Sònia BorrellSebastien Gagneux
Aug 19, 2015·The Lancet Infectious Diseases·Howard E Takiff, Oscar Feo
Jan 2, 2013·Tuberculosis·Fernanda S SpiesPedro Eduardo A da Silva
May 6, 2015·The Journal of Infection·B Molina-MoyaJ Dominguez
Nov 5, 2016·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·T SchönE Cambau
Sep 13, 2017·Antimicrobial Agents and Chemotherapy·John Z MetcalfeDavid M Engelthaler
Feb 6, 2019·Antimicrobial Agents and Chemotherapy·Sebastian M GygliErik C Böttger
Apr 30, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Fernanda MaruriTimothy R Sterling
Jun 19, 2019·Nature Reviews. Microbiology·Conor J MeehanAnnelies Van Rie
Jun 15, 2017·American Journal of Respiratory and Critical Care Medicine·John Z MetcalfeDavid M Engelthaler
Jun 25, 2015·Microbiology Spectrum·Claudine Mayer, Howard Takiff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.